Congenital Prothrombin Deficiency: An Update

 

 Buy Article Permissions and Reprints

Abstract

Prothrombin (factor II [FII]) deficiency is a rare inherited coagulation disorder, having a prevalence of approximately 1 in 2,000,000. Two phenotypes can be distinguished: (1) true hypoprothrombinemia (type I deficiency), characterized by concomitantly low levels of the zymogen antigen; and (2) dysprothrombinemia (type II deficiency), characterized by the normal or near-normal synthesis of a dysfunctional protein. In the latter case, recent studies showed that particular mutations in the catalytic domain of active thrombin can even impair the enzyme interaction with antithrombin, favoring thromboembolic diseases. In some cases, hypoprothrombinemia associated with dysprothrombinemia was also described in compound heterozygous defects. Prothrombin is essential for the development of mammalian organisms. No living patient with undetectable plasma prothrombin has been reported to date. Prothrombin is encoded by a ≈21 kb gene located on chromosome 11 and containing 14 exons. Thirty-nine different mutations have been identified and characterized in prothrombin deficiency. Many of these are present in the catalytic site, whereas some involve regulatory domains, such as the anion-binding exosite I, the Na⁺-binding loop, and the light A-chain. Most hypoprothrombinemia-associated mutations are missense, but nonsense mutations leading to stop codons and one single nucleotide deletion have also been identified. Finally, recent developments in the therapy of congenital prothrombin deficiency are presented and discussed.

• References

• 1 Lancellotti S, De Cristofaro R. Congenital prothrombin deficiency. Semin Thromb Hemost 2009; 35 (4) 367-381
  Article in Thieme ConnectPubMedGoogle Scholar
• 2 Barnhart MI. Cellular site for prothrombin synthesis. Am J Physiol 1960; 199: 360-366
  PubMedGoogle Scholar
• 3 Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 3 (8) 1894-1904
  CrossrefPubMedGoogle Scholar
• 4 Esmon CT. Regulation of blood coagulation. Biochim Biophys Acta 2000; 1477 (1-2) 349-360
  CrossrefPubMedGoogle Scholar
• 5 De Cristofaro R, De Candia E, Landolfi R, Rutella S, Hall SW. Structural and functional mapping of the thrombin domain involved in the binding to the platelet glycoprotein Ib. Biochemistry 2001; 40 (44) 13268-13273
  CrossrefPubMedGoogle Scholar
• 6 De Candia E, Hall SW, Rutella S, Landolfi R, Andrews RK, De Cristofaro R. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets. J Biol Chem 2001; 276 (7) 4692-4698
  CrossrefPubMedGoogle Scholar
• 7 Segers K, Dahlbäck B, Bock PE, Tans G, Rosing J, Nicolaes GA. The role of thrombin exosites I and II in the activation of human coagulation factor V. J Biol Chem 2007; 282 (47) 33915-33924
  CrossrefPubMedGoogle Scholar
• 8 Myles T, Yun TH, Leung LL. Structural requirements for the activation of human factor VIII by thrombin. Blood 2002; 100 (8) 2820-2826
  CrossrefPubMedGoogle Scholar
• 9 Isetti G, Maurer MC. Employing mutants to study thrombin residues responsible for factor XIII activation peptide recognition: a kinetic study. Biochemistry 2007; 46 (9) 2444-2452
  CrossrefPubMedGoogle Scholar
• 10 Bar-Shavit R, Kahn AJ, Mann KG, Wilner GD. Identification of a thrombin sequence with growth factor activity on macrophages. Proc Natl Acad Sci U S A 1986; 83 (4) 976-980
  CrossrefPubMedGoogle Scholar
• 11 Zetter BR, Antoniades HN. Stimulation of human vascular endothelial cell growth by a platelet-derived growth factor and thrombin. J Supramol Struct 1979; 11 (3) 361-370
  CrossrefPubMedGoogle Scholar
• 12 Seino Y, Ikeda U, Ikeda M , et al. Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine 1994; 6 (1) 87-91
  CrossrefPubMedGoogle Scholar
• 13 Fenton II JW. Regulation of thrombin generation and functions. Semin Thromb Hemost 1988; 14 (3) 234-240
  Article in Thieme ConnectPubMedGoogle Scholar
• 14 Siller-Matula JM, Schwameis M, Blann A, Mannhalter C, Jilma B. Thrombin as a multi-functional enzyme. Focus on in vitro and in vivo effects. Thromb Haemost 2011; 106 (6) 1020-1033
  Article in Thieme ConnectPubMedGoogle Scholar
• 15 Degen SJ, Davie EW. Nucleotide sequence of the gene for human prothrombin. Biochemistry 1987; 26 (19) 6165-6177
  CrossrefPubMedGoogle Scholar
• 16 Royle NJ, Irwin DM, Koschinsky ML, MacGillivray RT, Hamerton JL. Human genes encoding prothrombin and ceruloplasmin map to 11p11-q12 and 3q21-24, respectively. Somat Cell Mol Genet 1987; 13 (3) 285-292
  CrossrefPubMedGoogle Scholar
• 17 Akhavan S, Mannucci PM, Lak M , et al. Identification and three-dimensional structural analysis of nine novel mutations in patients with prothrombin deficiency. Thromb Haemost 2000; 84 (6) 989-997
  PubMedGoogle Scholar
• 18 Peyvandi F, Duga S, Akhavan S, Mannucci PM. Rare coagulation deficiencies. Haemophilia 2002; 8 (3) 308-321
  CrossrefPubMedGoogle Scholar
• 19 Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004; 104 (5) 1243-1252
  CrossrefPubMedGoogle Scholar
• 20 Acharya SS, Coughlin A, Dimichele DM. North American Rare Bleeding Disorder Study Group. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004; 2 (2) 248-256
  CrossrefPubMedGoogle Scholar
• 21 Girolami A, Scarano L, Saggiorato G, Girolami B, Bertomoro A, Marchiori A. Congenital deficiencies and abnormalities of prothrombin. Blood Coagul Fibrinolysis 1998; 9 (7) 557-569
  CrossrefPubMedGoogle Scholar
• 22 Peyvandi F, Cattaneo M, Inbal A, De Moerloose P, Spreafico M. Rare bleeding disorders. Haemophilia 2008; 14 (Suppl. 03) 202-210
  CrossrefPubMedGoogle Scholar
• 23 Sun WY, Witte DP, Degen JL , et al. Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc Natl Acad Sci U S A 1998; 95 (13) 7597-7602
  CrossrefPubMedGoogle Scholar
• 24 Xue J, Wu Q, Westfield LA , et al. Incomplete embryonic lethality and fatal neonatal hemorrhage caused by prothrombin deficiency in mice. Proc Natl Acad Sci U S A 1998; 95 (13) 7603-7607
  CrossrefPubMedGoogle Scholar
• 25 Iwahana H, Yoshimoto K, Shigekiyo T, Shirakami A, Saito S, Itakura M. Molecular and genetic analysis of a compound heterozygote for dysprothrombinemia of prothrombin Tokushima and hypoprothrombinemia. Am J Hum Genet 1992; 51 (6) 1386-1395
  PubMedGoogle Scholar
• 26 Wang W, Fu Q, Zhou R , et al. Prothrombin Shanghai: hypoprothrombinaemia caused by substitution of Gla29 by Gly. Haemophilia 2004; 10 (1) 94-97
  PubMedGoogle Scholar
• 27 Lanchantin GF, Hart DW, Friedmann JA, Saavedra NV, Mehl JW. Amino acid composition of human plasma prothrombin. J Biol Chem 1968; 243 (20) 5479-5485
  PubMedGoogle Scholar
• 28 Shapiro SS, McCord S. Prothrombin. Prog Hemost Thromb 1978; 4: 177-209
  PubMedGoogle Scholar
• 29 Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64 (6) 1057-1068
  CrossrefPubMedGoogle Scholar
• 30 Vouret-Craviari V, Boquet P, Pouysségur J, Van Obberghen-Schilling E. Regulation of the actin cytoskeleton by thrombin in human endothelial cells: role of Rho proteins in endothelial barrier function. Mol Biol Cell 1998; 9 (9) 2639-2653
  CrossrefPubMedGoogle Scholar
• 31 Schrör K, Bretschneider E, Fischer K , et al. Thrombin receptors in vascular smooth muscle cells - function and regulation by vasodilatory prostaglandins. Thromb Haemost 2010; 103 (5) 884-890
  Article in Thieme ConnectPubMedGoogle Scholar
• 32 Chung S, Kim JE, Park S, Han KS, Kim HK. Neutrophil and monocyte activation markers have prognostic impact in disseminated intravascular coagulation: in vitro effect of thrombin on monocyte CD163 shedding. Thromb Res 2011; 127 (5) 450-456
  CrossrefPubMedGoogle Scholar
• 33 Pou J, Rebollo A, Piera L , et al. Tissue factor pathway inhibitor 2 is induced by thrombin in human macrophages. Biochim Biophys Acta 2011; 1813 (6) 1254-1260
  CrossrefPubMedGoogle Scholar
• 34 Hurley A, Smith M, Karpova T , et al. Enhanced effector function of CD8+ T Cells from healthy controls and HIV-infected patients occurs through thrombin activation of protease-activated receptor 1. J Infect Dis 2013; 207 (4) 638-650
  CrossrefPubMedGoogle Scholar
• 35 Bai KJ, Chen BC, Pai HC , et al. Thrombin-induced CCN2 expression in human lung fibroblasts requires the c-Src/JAK2/STAT3 pathway. J Leukoc Biol 2013; 93 (1) 101-112
  CrossrefPubMedGoogle Scholar
• 36 Dugina TN, Kiseleva EV, Glusa E, Strukova SM. Activation of mast cells induced by agonists of proteinase-activated receptors under normal conditions and during acute inflammation in rats. Eur J Pharmacol 2003; 471 (2) 141-147
  CrossrefPubMedGoogle Scholar
• 37 Lee H, Hamilton JR. Physiology, pharmacology, and therapeutic potential of protease-activated receptors in vascular disease. Pharmacol Ther 2012; 134 (2) 246-259
  CrossrefPubMedGoogle Scholar
• 38 Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3 (8) 1800-1814
  CrossrefPubMedGoogle Scholar
• 39 Dihanich M, Kaser M, Reinhard E, Cunningham D, Monard D. Prothrombin mRNA is expressed by cells of the nervous system. Neuron 1991; 6 (4) 575-581
  CrossrefPubMedGoogle Scholar
• 40 Kim SR, Chung ES, Bok E , et al. Prothrombin kringle-2 induces death of mesencephalic dopaminergic neurons in vivo and in vitro via microglial activation. J Neurosci Res 2010; 88 (7) 1537-1548
  PubMedGoogle Scholar
• 41 Peyvandi F, Di Michele D, Bolton-Maggs PH, Lee CA, Tripodi A, Srivastava A. Project on Consensus Definitions in Rare Bleeeding Disorders of the Factor VIII/Factor IX Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. J Thromb Haemost 2012; 10 (9) 1938-1943
  CrossrefPubMedGoogle Scholar
• 42 Akhavan S, De Cristofaro R, Peyvandi F, Lavoretano S, Landolfi R, Mannucci PM. Molecular and functional characterization of a natural homozygous Arg67His mutation in the prothrombin gene of a patient with a severe procoagulant defect contrasting with a mild hemorrhagic phenotype. Blood 2002; 100 (4) 1347-1353
  CrossrefPubMedGoogle Scholar
• 43 Miyata T, Aruga R, Umeyama H, Bezeaud A, Guillin MC, Iwanaga S. Prothrombin Salakta: substitution of glutamic acid-466 by alanine reduces the fibrinogen clotting activity and the esterase activity. Biochemistry 1992; 31 (33) 7457-7462
  CrossrefPubMedGoogle Scholar
• 44 Morishita E, Saito M, Kumabashiri I, Asakura H, Matsuda T, Yamaguchi K. Prothrombin Himi: a compound heterozygote for two dysfunctional prothrombin molecules (Met-337—>Thr and Arg-388—>His). Blood 1992; 80 (9) 2275-2280
  PubMedGoogle Scholar
• 45 Di Cera E, Dang QD, Ayala YM. Molecular mechanisms of thrombin function. Cell Mol Life Sci 1997; 53 (9) 701-730
  CrossrefPubMedGoogle Scholar
• 46 Mota L, Ghosh K, Shetty S. Second trimester antenatal diagnosis in rare coagulation factor deficiencies. J Pediatr Hematol Oncol 2007; 29 (3) 137-139
  CrossrefPubMedGoogle Scholar
• 47 Van Creveld S. Congenital idiopathic hypoprothrombinemia. Acta Paediatr Suppl 1954; 43 (100) 245-255
  CrossrefPubMedGoogle Scholar
• 48 Miyawaki Y, Suzuki A, Fujita J , et al. Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med 2012; 366 (25) 2390-2396
  CrossrefPubMedGoogle Scholar
• 49 De Cristofaro R, Akhavan S, Altomare C, Carotti A, Peyvandi F, Mannucci PM. A natural prothrombin mutant reveals an unexpected influence of A-chain structure on the activity of human alpha-thrombin. J Biol Chem 2004; 279 (13) 13035-13043
  PubMedGoogle Scholar
• 50 De Cristofaro R, Carotti A, Akhavan S , et al. The natural mutation by deletion of Lys9 in the thrombin A-chain affects the pKa value of catalytic residues, the overall enzyme's stability and conformational transitions linked to Na+ binding. FEBS J 2006; 273 (1) 159-169
  CrossrefPubMedGoogle Scholar
• 51 Liu CC, Brustad E, Liu W, Schultz PG. Crystal structure of a biosynthetic sulfo-hirudin complexed to thrombin. J Am Chem Soc 2007; 129 (35) 10648-10649
  CrossrefPubMedGoogle Scholar
• 52 Napolitano M, Mariani G, Lapecorella M. Hereditary combined deficiency of the vitamin K-dependent clotting factors. Orphanet J Rare Dis 2010; 5: 21
  CrossrefPubMedGoogle Scholar
• 53 Oldenburg J, von Brederlow B, Fregin A , et al. Congenital deficiency of vitamin K dependent coagulation factors in two families presents as a genetic defect of the vitamin K-epoxide-reductase-complex. Thromb Haemost 2000; 84 (6) 937-941
  PubMedGoogle Scholar
• 54 Soute BA, Ulrich MM, Watson AD, Maddison JE, Ebberink RH, Vermeer C. Congenital deficiency of all vitamin K-dependent blood coagulation factors due to a defective vitamin K-dependent carboxylase in Devon Rex cats. Thromb Haemost 1992; 68 (5) 521-525
  PubMedGoogle Scholar
• 55 McMillan CW, Roberts HR. Congenital combined deficiency of coagulation factors II, VII, IX and X. Report of a case. N Engl J Med 1966; 274 (23) 1313-1315
  CrossrefPubMedGoogle Scholar
• 56 Brenner B, Tavori S, Zivelin A , et al. Hereditary deficiency of all vitamin K-dependent procoagulants and anticoagulants. Br J Haematol 1990; 75 (4) 537-542
  CrossrefPubMedGoogle Scholar
• 57 Lechler E. Use of prothrombin complex concentrates for prophylaxis and treatment of bleeding episodes in patients with hereditary deficiency of prothrombin, factor VII, factor X, protein C protein S, or protein Z. Thromb Res 1999; 95 (4) (Suppl. 01) S39-S50
  CrossrefPubMedGoogle Scholar
• 58 Owen Jr CA, Henriksen RA, McDuffie FC, Mann KG. Prothrombin Quick. A newly identified dysprothrombinemia. Mayo Clin Proc 1978; 53 (1) 29-33
  PubMedGoogle Scholar
• 59 Gill FM, Shapiro SS, Schwartz E. Severe congenital hypoprothrombinemia. J Pediatr 1978; 93 (2) 264-266
  PubMedGoogle Scholar
• 60 Ostermann H, Haertel S, Knaub S, Kalina U, Jung K, Pabinger I. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost 2007; 98 (4) 790-797
  Article in Thieme ConnectPubMedGoogle Scholar
• 61 Bjorkman S, Collins P. Measurement of factor VIII pharmacokinetics in routine clinical practice. J Thromb Haemost 2013; 11 (1) 180-182
  PubMedGoogle Scholar
• 62 Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Beriplex P/N Anticoagulation Reversal Study Group. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 2008; 6 (4) 622-631
  CrossrefPubMedGoogle Scholar
• 63 Bode W, Turk D, Karshikov A. The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci 1992; 1 (4) 426-471
  PubMedGoogle Scholar
• 64 Girolami A, Santarossa L, Scarparo P, Candeo N, Girolami B. True congenital prothrombin deficiency due to a 'new' mutation in the pre-propeptide (ARG-39 GLN). Acta Haematol 2008; 120 (2) 82-86
  CrossrefPubMedGoogle Scholar
• 65 Wong AY, Hewitt J, Clarke BJ , et al. Severe prothrombin deficiency caused by prothrombin-Edmonton (R-4Q) combined with a previously undetected deletion. J Thromb Haemost 2006; 4 (12) 2623-2628
  CrossrefPubMedGoogle Scholar
• 66 Strijks E, Poort SR, Renier WO, Gabreëls FJ, Bertina RM. Hereditary prothrombin deficiency presenting as intracranial haematoma in infancy. Neuropediatrics 1999; 30 (6) 320-324
  Article in Thieme ConnectPubMedGoogle Scholar
• 67 Poort SR, Michiels JJ, Reitsma PH, Bertina RM. Homozygosity for a novel missense mutation in the prothrombin gene causing a severe bleeding disorder. Thromb Haemost 1994; 72 (6) 819-824
  PubMedGoogle Scholar
• 68 Sun WY, Ruiz-Saez A, Burkart MC, Bosch N, Degen SJ. Prothrombin carora: hypoprothrombinaemia caused by substitution of Tyr-44 by Cys. Br J Haematol 1999; 105 (3) 670-672
  CrossrefPubMedGoogle Scholar
• 69 Kulkarni B, Kanakia S, Ghosh K, Shetty S. Prothrombin Mumbai causes severe prothrombin deficiency due to a novel Cys90Ser mutation. Ann Hematol 2012; 91 (10) 1667-1668
  CrossrefPubMedGoogle Scholar
• 70 Poort SR, Landolfi R, Bertina RM. Compound heterozygosity for two novel missense mutations in the prothrombin gene in a patient with a severe bleeding tendency. Thromb Haemost 1997; 77 (4) 610-615
  PubMedGoogle Scholar
• 71 Board PG, Shaw DC. Determination of the amino acid substitution in human prothrombin type 3 (157 Glu leads to Lys) and the localization of a third thrombin cleavage site. Br J Haematol 1983; 54 (2) 245-254
  CrossrefPubMedGoogle Scholar
• 72 Miyata T, Zheng YZ, Kato A, Kato H. A point mutation (Arg271→Cys) of a homozygote for dysfunctional prothrombin, prothrombin Obihiro, which has a region of high sequence variability. Br J Haematol 1995; 90 (3) 688-692
  CrossrefPubMedGoogle Scholar
• 73 James HL, Kim DJ, Zheng DQ, Girolami A. Prothrombin Padua I: incomplete activation due to an amino acid substitution at a factor Xa cleavage site. Blood Coagul Fibrinolysis 1994; 5 (5) 841-844
  CrossrefPubMedGoogle Scholar
• 74 François D, Chevreaud C, Vignon D, de Mazancourt P. Prothrombin Suresnes: a case of homozygous F299V mutation responsible for hypodysprothrombinemia. Haematologica 2006; 91 (3) 431-432
  PubMedGoogle Scholar
• 75 Lefkowitz JB, Haver T, Clarke S , et al. The prothrombin Denver patient has two different prothrombin point mutations resulting in Glu-300→Lys and Glu-309→Lys substitutions. Br J Haematol 2000; 108 (1) 182-187
  CrossrefPubMedGoogle Scholar
• 76 Akhavan S, Rocha E, Zeinali S, Mannucci PM. Gly319 → arg substitution in the dysfunctional prothrombin Segovia. Br J Haematol 1999; 105 (3) 667-669
  CrossrefPubMedGoogle Scholar
• 77 Sun WY, Burkart MC, Holahan JR, Degen SJ. Prothrombin San Antonio: a single amino acid substitution at a factor Xa activation site (Arg320 to His) results in dysprothrombinemia. Blood 2000; 95 (2) 711-714
  PubMedGoogle Scholar
• 78 Tamary H, Surrey S, Augustine J, Shalmon L, Schwartz E, Rappaport EF. Molecular analysis of a compound heterozygote for hypoprothrombinemia and dysprothrombinemia (-G 7248/7249 and ARG 340 TRP). Blood Coagul Fibrinolysis 1997; 8 (6) 337-343
  CrossrefPubMedGoogle Scholar
• 79 Jayandharan G, Viswabandya A, Baidya S , et al. Molecular genetics of hereditary prothrombin deficiency in Indian patients: identification of a novel Ala362 → Thr (Prothrombin Vellore 1) mutation. J Thromb Haemost 2005; 3 (7) 1446-1453
  CrossrefPubMedGoogle Scholar
• 80 Henriksen RA, Owen WG, Nesheim ME, Mann KG. Identification of a congenital dysthrombin, thrombin Quick. J Clin Invest 1980; 66 (5) 934-940
  CrossrefPubMedGoogle Scholar
• 81 O'Marcaigh AS, Nichols WL, Hassinger NL , et al. Genetic analysis and functional characterization of prothrombins Corpus Christi (Arg382-Cys), Dhahran (Arg271-His), and hypoprothrombinemia. Blood 1996; 88 (7) 2611-2618
  PubMedGoogle Scholar
• 82 Girolami A, Coccheri S, Palareti G, Poggi M, Burul A, Cappellato G. Prothrombin Molise: a “new” congenital dysprothrombinemia, double heterozygosis with an abnormal prothrombin and “true” prothrombin deficiency. Blood 1978; 52 (1) 115-125
  PubMedGoogle Scholar
• 83 Iwahana H, Yoshimoto K, Shigekiyo T, Shirakami A, Saito S, Itakura M. Detection of a single base substitution of the gene for prothrombin Tokushima. The application of PCR-SSCP for the genetic and molecular analysis of dysprothrombinemia. Int J Hematol 1992; 55 (1) 93-100
  PubMedGoogle Scholar
• 84 Kling SJ, Jones KA, Rodgers GM. A second case of prothrombin Puerto Rico I in the United States. Am J Hematol 2007; 82 (7) 661-662
  CrossrefPubMedGoogle Scholar
• 85 Lefkowitz JB, Weller A, Nuss R, Santiago-Borrero PJ, Brown DL, Ortiz IR. A common mutation, Arg457—>Gln, links prothrombin deficiencies in the Puerto Rican population. J Thromb Haemost 2003; 1 (11) 2381-2388
  CrossrefPubMedGoogle Scholar
• 86 Stanchev H, Philips M, Villoutreix BO, Aksglaede L, Lethagen S, Thorsen S. Prothrombin deficiency caused by compound heterozygosity for two novel mutations in the prothrombin gene associated with a bleeding tendency. Thromb Haemost 2006; 95 (1) 195-198
  PubMedGoogle Scholar
• 87 Henriksen RA, Dunham CK, Miller LD , et al. Prothrombin Greenville, Arg517—>Gln, identified in an individual heterozygous for dysprothrombinemia. Blood 1998; 91 (6) 2026-2031
  PubMedGoogle Scholar
• 88 Sekine O, Sugo T, Ebisawa K , et al. Substitution of Gly-548 to Ala in the substrate binding pocket of prothrombin Perijá leads to the loss of thrombin proteolytic activity. Thromb Haemost 2002; 87 (2) 282-287
  PubMedGoogle Scholar
• 89 Sun WY, Smirnow D, Jenkins ML, Degen SJ. Prothrombin Scranton: substitution of an amino acid residue involved in the binding of Na+ (LYS-556 to THR) leads to dysprothrombinemia. Thromb Haemost 2001; 85 (4) 651-654
  PubMedGoogle Scholar
• 90 Henriksen RA, Mann KG. Substitution of valine for glycine-558 in the congenital dysthrombin thrombin Quick II alters primary substrate specificity. Biochemistry 1989; 28 (5) 2078-2082
  CrossrefPubMedGoogle Scholar
• 91 Poort SR, Njo KT, Vos HL, Bertina RM. Two novel mutations in the prothrombin gene cause severe bleeding in a compound heterozygous patient. Blood Coagul Fibrinolysis 1998; 9 (8) 761-764
  CrossrefPubMedGoogle Scholar